← Eichor
Study identifier: NCT06099366 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Condition: Lymphoblastic Leukemia in Children  ·  Sponsor: Hee Young Ju

PhasePhase 2
Planned participants116
Who can joinAll sexes, 1 Year to 9 Years
Healthy volunteersNo

About this study

Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.

This description comes directly from the study's public registry record.

Talk to the study team

Hee Young Ju, MD, Phd  ·  82-2-3410-0865  ·  heeyoung.ju@samsung.com

hyunjung Shin  ·  82-2-3410-6763  ·  hjds.shin@samsung.com

Always discuss trial participation with your own doctor first.

Locations (9)

Asan Medical CenterSeoul, Other (Non U.s.), South KoreaRecruiting
Samsung Medical CenterSeoul, Other (Non U.s.), South KoreaRecruiting
Pusan National University Yangsan HospitalYangsan, Yangsan-si, South KoreaRecruiting
Chonnam National University Hwasun HospitalHwasun, South KoreaNot Yet Recruiting
Jeju National University HospitalJeju City, South KoreaNot Yet Recruiting
Korea University Anam HospitalSeoul, South KoreaNot Yet Recruiting
Seoul National University HospitalSeoul, South KoreaRecruiting
Severance HospitalSeoul, South KoreaRecruiting
Seoul saint Mary's HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06099366